Table 1.
Baseline characteristics
| Characteristics | Atez/Bev group (N = 77) (No, %; Mean ± SD) |
TACE-Atez/Bev group (N = 62) (No, %; Mean ± SD) |
P value |
|---|---|---|---|
| Gender | 0.930 | ||
| Male | 65 (84.4%) | 52 (83.9%) | |
| Female | 12 (15.6%) | 10 (16.1%) | |
| Age (years) | 52.8 ± 11.0 | 55.8 ± 11.2 | 0.108 |
| Hepatitis | 0.449 | ||
| Hepatitis B | 59 (76.6%) | 44 (71.0%) | |
| Other | 18 (23.4%) | 18 (29.0%) | |
| Child-Pugh score | 0.832 | ||
| A | 51 (66.2%) | 40 (64.5%) | |
| B | 26 (33.8%) | 22 (35.5%) | |
| TB (µmol/L) | 19.8 ± 11.2 | 18.3 ± 9.4 | 0.422 |
| Albumin (g/L) | 35.8 ± 4.8 | 34.6 ± 3.4 | 0.103 |
| PT(s) | 14.3 ± 1.2 | 14.1 ± 1.5 | 0.560 |
| AST (µmol/L) | 60.7 ± 47.2 | 66.8 ± 50.0 | 0.459 |
| ALT (µmol/L) | 43.4 ± 24.5 | 43.2 ± 24.2 | 0.961 |
| PLR | 128.9 ± 63.3 | 146.4 ± 63.5 | 0.108 |
| NLR | 3.0 ± 2.0 | 3.5 ± 1.8 | 0.090 |
| Tumor size (cm) | 8.9 ± 3.5 | 8.4 ± 4.6 | 0.457 |
| Tumor number | 0.861 | ||
| ≤ 3 | 12 (15.6%) | 9 (14.5%) | |
| >3 | 65 (84.4%) | 53 (85.5%) | |
| α-Fetoprotein level | 0.569 | ||
| >400 ng/mL | 36 (46.7%) | 32 (51.6%) | |
| ≤ 400 ng/ml | 41 (53.2%) | 30 (48.4%) | |
| ECOG | 0.421 | ||
| 0 | 32 (41.6%) | 30 (48.4%) | |
| 1 | 45 (58.4%) | 32 (51.6%) | |
| Vascular invasion | 0.906 | ||
| Absent | 34 (44.2%) | 28 (45.2%) | |
| Present | 43 (55.8%) | 34 (54.8%) | |
| Extrahepatic spread | 0.538 | ||
| Absent | 32 (41.6%) | 29 (46.8%) | |
| Present | 45 (58.4%) | 33 (53.2%) | |
| Ascites | 0.114 | ||
| Absent | 46 (59.7%) | 45 (72.6%) | |
| Present | 31 (40.3%) | 17 (27.4%) | |
Atez/Bev Atezolizumab/bevacizumab, TACE Transarterial chemoembolization, SD Standard deviation, BCLC Barcelona Clinical Liver Cancer, TB Total bilirubin, PT Prothrombin time, AST Aspartate aminotransferase, ALT Alanine aminotransferase, PLR Platelet-to-lymphocyte ratio, NLR Neutrophil-to-lymphocyte ratio, ECOG Eastern Cooperative Oncology Group